Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$164.66 - $218.08 $20,747 - $27,478
-126 Reduced 0.35%
35,415 $5.99 Million
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $2.98 Million - $4.06 Million
16,913 Added 90.79%
35,541 $7.71 Million
Q1 2023

May 15, 2023

SELL
$161.33 - $204.36 $3.64 Million - $4.61 Million
-22,537 Reduced 54.75%
18,628 $3.38 Million
Q4 2022

Feb 14, 2023

SELL
$191.53 - $236.82 $42,519 - $52,574
-222 Reduced 0.54%
41,165 $8.09 Million
Q3 2022

Feb 14, 2023

SELL
$123.79 - $277.42 $785,323 - $1.76 Million
-6,344 Reduced 13.29%
41,387 $9.31 Million
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $785,323 - $1.76 Million
-6,344 Reduced 13.29%
41,387 $9.31 Million
Q2 2022

Feb 14, 2023

SELL
$93.97 - $143.33 $87,298 - $133,153
-929 Reduced 1.91%
47,731 $6.04 Million
Q2 2022

Aug 15, 2022

SELL
$93.97 - $143.33 $87,298 - $133,153
-929 Reduced 1.91%
47,731 $6.04 Million
Q1 2022

Feb 14, 2023

BUY
$98.9 - $132.37 $719,299 - $962,727
7,273 Added 17.57%
48,660 $6.17 Million
Q1 2022

May 13, 2022

SELL
$98.9 - $132.37 $2.55 Million - $3.42 Million
-25,811 Reduced 34.66%
48,660 $6.17 Million
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $98,358 - $141,706
889 Added 1.21%
74,471 $9.76 Million
Q3 2021

Nov 15, 2021

BUY
$101.2 - $125.87 $274,150 - $340,981
2,709 Added 3.82%
73,582 $9 Million
Q2 2021

Aug 13, 2021

SELL
$107.45 - $135.95 $10,959 - $13,866
-102 Reduced 0.14%
70,873 $8.08 Million
Q1 2021

May 14, 2021

BUY
$95.46 - $133.08 $1.73 Million - $2.42 Million
18,166 Added 34.4%
70,975 $8.53 Million
Q4 2020

Feb 12, 2021

BUY
$75.23 - $109.23 $159,938 - $232,222
2,126 Added 4.19%
52,809 $5.37 Million
Q3 2020

Nov 13, 2020

SELL
$71.31 - $109.74 $25,885 - $39,835
-363 Reduced 0.71%
50,683 $3.92 Million
Q2 2020

Aug 14, 2020

BUY
$62.14 - $117.21 $3.17 Million - $5.98 Million
51,046 New
51,046 $5.69 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.